Skip to main content
Clinical Trials/NCT06954142
NCT06954142RecruitingNot Applicable

Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia - RELIEF Trial. A Cluster-randomised Multiple Period Cross-over Trial.

University Children's Hospital Basel18 sites in 1 country750 target enrollmentStarted: July 12, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
750
Locations
18
Primary Endpoint
Bronchopulmonary dysplasia (BPD)

Study Overview

Brief Summary

The aim of this study is to determine whether restricted fluid intake (135 ±5 mL/kg/day) compared to liberal fluid intake (165 ±5 mL/kg/day) from day 8 of life reduces the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age or prior death in preterm infants born <30 weeks gestational age.

Detailed Description

Complications of preterm birth remain the leading cause of death in children under five years of age worldwide, accounting for approximately one million deaths annually. Among the survivors, bronchopulmonary dysplasia (BPD) is the most common severe complication. BPD is a chronic lung disease characterized by prolonged need for respiratory support and oxygen therapy, poor postnatal growth, and long-term impairments in lung function and neurodevelopment.

Despite advancements in neonatal care, BPD is the most common chronic lung disease in infancy and associated with increased mortality, repeated hospitalisation throughout childhood, impaired lung function up into adulthood, and long-term neurodevelopmental impairment. The incidence of BPD has remained stable over the past 15 years. This is likely due to the improved survival of extremely preterm infants, who are at the highest risk for BPD.

A key feature of evolving BPD is the accumulation of interstitial pulmonary edema, which reduces lung compliance and increases the need for respiratory support, thereby perpetuating a cycle of lung damage.

Currently, diuretics are sometimes used to manage pulmonary edema in preterm infants. While they can improve lung function in the short term, they come with potential risks including bone demineralization, nephrotoxicity, electrolyte imbalances, and impaired growth.

As a potentially safer alternative, fluid restriction is sometimes used to prevent or manage pulmonary edema. It is hypothesized to improve lung mechanics and reduce the need for respiratory support, without the adverse effects associated with medications. However, there is no robust evidence on optimal fluid targets in these patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
8 Days to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Hospitalised preterm infants born before 30 weeks 0 days gestation
  • •Signed informed consent for further research use of health-related data

Exclusion Criteria

  • •congenital malformations
  • •diseases likely to affect life expectancy, lung function, fluid strategy, or neurodevelopment
  • •renal disease requiring fluid management outside the clinical standard of care
  • •congenital heart disease not including patent ductus arteriosus (PDA)

Arms & Interventions

Fluid restriction

Experimental

Fluid restriction strategy (fluid target 135 ±5 mL/kg/d). This is standard of care.

Intervention: Fluid restriction (Other)

Liberal fluid intake

Active Comparator

Liberal fluid intake strategy (fluid target 165 ± 5 mL/kg/d) in line with international best practice recommendations on nutrition.

Intervention: Liberal fluid intake (Other)

Outcomes

Primary Outcomes

Bronchopulmonary dysplasia (BPD)

Time Frame: From enrolment to 36 weeks postmenstrual age

Proportion of infants with BPD measured at 36 weeks postmenstrual age or prior death.

Secondary Outcomes

  • Days to reach full feeds(From enrolment to 36 weeks postmenstrual age)
  • Need of diuretics(From enrolment to 36 weeks postmenstrual age)
  • Need of corticosteroids(From enrolment to 36 weeks postmenstrual age)
  • Growth(at birth and 36 weeks postmenstrual age)
  • Daily caloric intake(From enrolment to 36 weeks postmenstrual age)
  • Dehydration(From enrolment to 36 weeks postmenstrual age)
  • Fluid overload(From enrolment to 36 weeks postmenstrual age)
  • Age at discharge(At first discharge home, on average 37 weeks postmenstrual age)
  • Tube feeding(At first discharge home, on average 37 weeks postmenstrual age)
  • Complications of prematurity(From enrolment to 36 weeks postmenstrual age)
  • Need of respiratory support(At first discharge home, on average 37 weeks postmenstrual age)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (18)

Loading locations...

Similar Trials